[1]
|
刘祖国, 杨文照. 干眼症的发病机制[J]. 眼科, 2005, 14(5): 342-345.
|
[2]
|
Benitez-del-Castillo, J.M., del Rio, T., Ira-dier, T., Hernández, J.L., Castillo, A. and Garcia-Sanchez, J. (2001) Decrease in Tear Secretion and Corneal Sensitivity after Laser in Situ Keratomileusis. Cornea, 20, 30-32.
https://doi.org/10.1097/00003226-200101000-00005
|
[3]
|
(2007) The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). The Ocular Surface, 5, 75-92.
https://doi.org/10.1016/S1542-0124(12)70081-2
|
[4]
|
Qian, L. and Wei, W. (2022) Identified Risk Factors for Dry Eye Syndrome: A Systematic Review and Meta-Analysis. PLOS ONE, 17, e0271267. https://doi.org/10.1371/journal.pone.0271267
|
[5]
|
Begley, C.G., Caffery, B., Nichols, K.K. and Chalmers R. (2000) Responses of Contact Lens Wearers to a Dry Eye Survey. Optometry and Vision Science, 77, 40-46. https://doi.org/10.1097/00006324-200001000-00012
|
[6]
|
Johnson, M.E. (2009) The Association between Symp-toms of Discomfort and Signs in Dry Eye. The Ocular Surface, 7, 199-211. https://doi.org/10.1016/S1542-0124(12)70187-8
|
[7]
|
Ganesalingam, K., Ismail, S., Sherwin, T. and Craig, J.P. (2019) Molecular Evidence for the Role of Inflammation in Dry Eye Disease. Clinical & Experimental Optometry, 102, 446-454. https://doi.org/10.1111/cxo.12849
|
[8]
|
Fahr, A. (1993) Cyclosporin Clinical Pharmacokinetics. Clinical Pharmacokinetics, 24, 472-495.
https://doi.org/10.2165/00003088-199324060-00004
|
[9]
|
Hunter, P.A., Wilhelmus, K.R., Rice, N.S. and Jones, B.R. (1981) Cyclosporin A Applied Topically to the Recipient Eye Inhibits Corneal Graft Rejection. Clinical and Exper-imental Immunology, 45, 173-177.
|
[10]
|
Lallemand, F., Felt-Baeyens, O., Besseghir, K., Behar-Cohen, F. and Gurny, R. (2003) Cyclosporine A Delivery to the Eye: A Pharmaceutical Challenge. European Journal of Pharmaceutics and Bio-pharmaceutics, 56, 307-318.
https://doi.org/10.1016/S0939-6411(03)00138-3
|
[11]
|
Liang, H., Baudouin, C., Daull, P., Garrigue, J.-S. and Brignole-Baudouin, F. (2012) Ocular Safety of Cationic Emulsion of Cyclosporine in an in Vitro Corneal Wound-Healing Model and an Acute in Vivo Rabbit Model. Molecular Vision, 18, 2195-2204.
|
[12]
|
Wan, K.H., Chen, L.J. and Young, A.L. (2015) Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis. The Ocular Surface, 13, 213-225.
https://doi.org/10.1016/j.jtos.2014.12.006
|
[13]
|
赵慧, 刘祖国, 杨文照, 肖辛野, 陈景尧, 李奇渊, 钟桃玲. 我国干眼问卷的研制及评估[J]. 中华眼科杂志, 2015, 51(9): 647-654.
|
[14]
|
Şimşek, C., Doğru, M., Kojima, T. and Tsubota, K. (2018) Current Management and Treatment of Dry Eye Disease. Turkish Journal of Ophthalmology, 48, 309-313. https://doi.org/10.4274/tjo.69320
|
[15]
|
Corbett, K.M., Ford, L., Warren, D.B., Pouton, C.W. and Chalmers, D.K. (2021) Cyclosporin Structure and Permeability: From A to Z and beyond. Journal of Medicinal Chemis-try, 64, 13131-13151.
https://doi.org/10.1021/acs.jmedchem.1c00580
|
[16]
|
Hyun, S., Li, L., Yoon, K.C. and Yu, J. (2019) An Amphi-pathic Cell Penetrating Peptide Aids Cell Penetration of Cyclosporin A and Increases Its Therapeutic Effect in an in Vivo Mouse Model for Dry Eye Disease. Chemical Communications, 55, 13657-13660. https://doi.org/10.1039/C9CC05960A
|
[17]
|
Brignole, F., Pisella, P.J., De Saint Jean, M., Goldschild, M., Goguel, A. and Baudouin, C. (2001) Flow Cytometric Analysis of Inflammatory Markers in KCS: 6-Month Treatment with Top-ical Cyclosporin A. Investigative Ophthalmology & Visual Science, 42, 90-95.
|
[18]
|
Kunert, K.S., Tisdale, A.S. and Gipson, I.K. (2002) Goblet Cell Numbers and Epithelial Proliferation in the Conjunctiva of Patients with Dry Eye Syn-drome Treated with Cyclosporine. Archives of Ophthalmology, 120, 330-337.
https://doi.org/10.1001/archopht.120.3.330
|
[19]
|
Kunert, K.S., Tisdale, A.S., Stern, M.E., Smith, J.A. and Gipson, I.K. (2000) Analysis of Topical Cyclosporine Treatment of Patients with Dry Eye Syndrome: Effect on Conjunctival Lymphocytes. Archives of Ophthalmology, 118, 1489-1496. https://doi.org/10.1001/archopht.118.11.1489
|
[20]
|
Strong, B., Farley, W., Stern, M.E. and Pflugfelder, S.C. (2005) Topical Cyclosporine Inhibits Conjunctival Epithelial Apoptosis in Experimental Murine Keratoconjunctivitis Sicca. Cor-nea, 24, 80-85.
https://doi.org/10.1097/01.ico.0000133994.22392.47
|
[21]
|
Kim, H.-Y., Lee, J.-E., Oh, H.-N., Song, J.-W., Han, S.-Y. and Lee, J.-S. (2018) Clinical Efficacy of Combined Topical 0.05% Cyclosporine A and 0.1% Sodium Hyaluronate in the Dry Eyes with Meibomian Gland Dysfunction. International Journal of Ophthalmology, 11, 593-600.
|
[22]
|
郭晓红, 吴越. 睑板腺按摩联合双氯芬酸钠滴眼液及玻璃酸钠滴眼液治疗睑板腺功能障碍性干眼症的疗效观察[J]. 现代实用医学, 2018, 30(9): 1214-1215.
|
[23]
|
吴宝玲. 双氯芬酸钠联合玻璃酸钠滴眼液治疗白内障术后干眼症患者的疗效[J]. 中国药物经济学, 2021, 16(6): 56-58.
|
[24]
|
Bai, R., Liu, L.-P., Chen, Z. and Ma, Q. (2022) Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease. Journal of Ophthalmology, 2022, Article ID: 2334077.
https://doi.org/10.1155/2022/2334077
|